These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1363649)

  • 1. Clonal analysis of agnogenic myeloid metaplasia.
    Kreipe H; Jaquet K; Felgner J; Parwaresch MR
    Leuk Lymphoma; 1992 Dec; 8(6):459-64. PubMed ID: 1363649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia.
    Kreipe H; Jaquet K; Felgner J; Radzun HJ; Parwaresch MR
    Blood; 1991 Oct; 78(7):1814-7. PubMed ID: 1680495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.
    Jacobson RJ; Salo A; Fialkow PJ
    Blood; 1978 Feb; 51(2):189-94. PubMed ID: 620081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating haemopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis.
    Colović MD; Wiernik PH; Janković GM; Vidović AD; Janosević S; Basara NM
    Eur J Haematol; 1999 Mar; 62(3):155-9. PubMed ID: 10089892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
    Martyré MC
    Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
    Kreipe HH
    Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphometric analysis of myelofibrosis in agnogenic myeloid metaplasia and chronic myelogenous leukemia.
    Ohsaka A; Miura Y; Takahashi A; Yokoyama T
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1991; 60(6):399-405. PubMed ID: 1683056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased erythrocytic and neutrophilic progenitors in myelofibrosis with myeloid metaplasia.
    Ohl S; Carsten AL; Chanana AD; Chikkappa G; Cronkite EP
    Eur J Cancer (1965); 1976 Feb; 12(2):131-5. PubMed ID: 1063073
    [No Abstract]   [Full Text] [Related]  

  • 10. Blastic phase of agnogenic myeloid metaplasia simulating malignant lymphoma.
    Cehreli C; Ezdinli EZ; Li CY; Krmpotic E
    Cancer; 1976 Sep; 38(3):1297-305. PubMed ID: 953969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current perspective in agnogenic myeloid metaplasia.
    Tefferi A; Silverstein MN
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():169-71. PubMed ID: 8951788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data.
    Thiele J; Zankovich R; Steinberg T; Kremer B; Fischer R; Diehl V
    Acta Haematol; 1989; 81(4):192-202. PubMed ID: 2474228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays.
    Jones LC; Tefferi A; Vuong PT; Desmond JC; Hofmann WK; Koeffler HP
    Stem Cells; 2005 May; 23(5):631-7. PubMed ID: 15849170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive myelofibrosis in agnogenic myeloid metaplasia.
    Lohmann TP; Beckman EN
    Arch Pathol Lab Med; 1983 Nov; 107(11):593-4. PubMed ID: 6688716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelofibrosis in chronic granulocytic leukaemia.
    Clough V; Geary CG; Hashmi K; Davson J; Knowlson T
    Br J Haematol; 1979 Aug; 42(4):515-26. PubMed ID: 289409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marrow fibrosis does not account for circulating CD34+ cells in myelofibrosis with myeloid metaplasia.
    Samuelson SJ; Popat U; Prchal JT
    Haematologica; 2007 Apr; 92(4):e47. PubMed ID: 17405759
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia.
    Reilly JT
    Semin Oncol; 2005 Aug; 32(4):359-64. PubMed ID: 16202681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement.
    Tsukamoto N; Morita K; Maehara T; Okamoto K; Sakai H; Karasawa M; Naruse T; Omine M
    Br J Haematol; 1994 Feb; 86(2):253-8. PubMed ID: 7911034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased granulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia.
    Chikkappa G; Carsten AL; Chanana AD; Chandra P; Cronkite EP
    Am J Hematol; 1978; 4(2):121-31. PubMed ID: 677118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.